<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296322</url>
  </required_header>
  <id_info>
    <org_study_id>AMC-ONCGI-0102</org_study_id>
    <nct_id>NCT00296322</nct_id>
  </id_info>
  <brief_title>Trial of Adjuvant Chemotherapy for Gastric Cancer</brief_title>
  <official_title>A Phase III Randomized Controlled Trial of Adjuvant Chemotherapy for Gastric Adenocarcinoma: Mitomycin and Doxifluridine Versus Intraperitoneal Chemotherapy and Mitomycin, Doxifluridine, and Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ulsan University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with
      early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine
      compared to mitomycin plus doxifluridine in resected advanced gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stomach cancer is the most common cancer in Korea and one of the major health problems
      worldwide. The most effective treatment for gastric cancer is curative surgical resection of
      primary tumor. However, a substantial number of patients eventually die of recurrences after
      curative resection. A number of randomized trials investigating the role of adjuvant
      chemotherapy have been conducted. However, the efficacy of adjuvant chemotherapy is still
      controversial and varied between Western and Asian trials. Meta-analysis of Western trials
      didn't demonstrate the benefit of adjuvant chemotherapy after curative resection. Conversely,
      some Asian studies have demonstrated the efficacy of adjuvant chemotherapy after curative
      resection. In a previous study, mitomycin plus tegafur prolonged the survival in resected
      gastric cancer compared to no treatment.

      This study is designed to evaluate the efficacy of the intraperitoneal chemotherapy with
      early mitomycin administration and adding cisplatin to prolonged treatment with doxifluridine
      compared to mitomycin plus doxifluridine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2001</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse-free Survival</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Profile (According to NCI CTC Version 2.0)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">528</enrollment>
  <condition>Stomach Cancer</condition>
  <arm_group>
    <arm_group_label>Mitomycin-C, Doxifluridine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mitomycin-C, Doxifluridine, Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin, mitomycin-C, doxifluridine</intervention_name>
    <description>Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)</description>
    <arm_group_label>Mitomycin-C, Doxifluridine</arm_group_label>
    <arm_group_label>Mitomycin-C, Doxifluridine, Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically proven gastric adenocarcinoma

          -  Grossly serosa invasion of primary tumor is suspicious

          -  Curative resection was done

          -  Stage II, IIIA, IIIB, IV (including T4, lesions or N3, but excluding M1 lymph node
             metastasis)

          -  Age: 18-69 years old

          -  Performance status: Eastern Cooperative Oncology Group (ECOG) 0-2

          -  Adequate bone marrow function (white blood cell counts ≥ 4,000/ul, platelet count ≥
             100,000/ul, hemoglobin ≥ 10 g/dl)

          -  Adequate renal function (serum creatinine≤ 1.5)

          -  Adequate liver function (serum bilirubin ≤1.5 mg/dl, aspartate aminotransferase
             (AST)/alanine aminotransferase (ALT) ≤ 3 x normal upper limit)

          -  Written informed consent was signed by the patient

        Exclusion Criteria:

          -  Previous chemotherapy or radiotherapy

          -  Active ongoing infection which antibiotic treatment is needed

          -  Pregnant or lactating women

          -  Psychosis or convulsion disorder

          -  Ascites in preoperative abdomen computed tomography (CT)

          -  Systemic disease which interfere the administration of chemotherapy

          -  Postoperative pathologic stage IA, IB

          -  Postoperative pathology indicates that resection margin is involved

          -  Previous history of other malignancy except cured non-malignant skin cancer and
             uterine cervical cancer in situ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, M.D.,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2006</study_first_submitted>
  <study_first_submitted_qc>February 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <results_first_submitted>July 19, 2012</results_first_submitted>
  <results_first_submitted_qc>August 1, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 6, 2012</results_first_posted>
  <last_update_submitted>August 7, 2013</last_update_submitted>
  <last_update_submitted_qc>August 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>stomach cancer</keyword>
  <keyword>adjuvant chemotherapy</keyword>
  <keyword>mitomycin</keyword>
  <keyword>cisplatin</keyword>
  <keyword>doxifluridine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxifluridine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Although this study was originally designed to include 528 patients, a total 521 patients could be enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Mitomycin and Short-term Fluoropyrimidine</title>
          <description>Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)</description>
        </group>
        <group group_id="P2">
          <title>iceMFP</title>
          <description>Intraperitoneal cisplatin, mitomycin, cisplatin and long-term flouropyrimidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="258"/>
                <participants group_id="P2" count="263"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="184"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mitomycin and Short-term Fluoropyrimidine</title>
          <description>Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)</description>
        </group>
        <group group_id="B2">
          <title>iceMFP</title>
          <description>Intraperitoneal cisplatin, mitomycin, cisplatin and long-term flouropyrimidine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="258"/>
            <count group_id="B2" value="263"/>
            <count group_id="B3" value="521"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="224"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.87" spread="10.093"/>
                    <measurement group_id="B2" value="52.23" spread="11.016"/>
                    <measurement group_id="B3" value="53.04" spread="10.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="351"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relapse-free Survival</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitomycin and Short-term Fluoropyrimidine</title>
            <description>Mitomycin and short-term flouropyrimidine</description>
          </group>
          <group group_id="O2">
            <title>iceMFP</title>
            <description>Intraperitoneal cisplatin, mitomycin, cisplatin and long-term flouropyrimidine</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse-free Survival</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="43.4" upper_limit="56.6"/>
                    <measurement group_id="O2" value="60.2" lower_limit="53.6" upper_limit="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Profile (According to NCI CTC Version 2.0)</title>
        <description>Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will.</description>
        <time_frame>up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitomycin and Short-term Fluoropyrimidine</title>
            <description>Mitomycin and short-term flouropyrimidine</description>
          </group>
          <group group_id="O2">
            <title>iceMFP</title>
            <description>Intraperitoneal cisplatin, mitomycin, cisplatin and long-term flouropyrimidine</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity Profile (According to NCI CTC Version 2.0)</title>
          <description>Because safety profile in oncology study is evaluated for each toxicity, it is impossible to present the overall patient number. Instead, we presented the number of patients who declined study therapy due to adverse events or patient will.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mitomycin and Short-term Fluoropyrimidine</title>
            <description>Mitomycin and short-term flouropyrimidine</description>
          </group>
          <group group_id="O2">
            <title>iceMFP</title>
            <description>Intraperitoneal cisplatin, mitomycin, cisplatin and long-term flouropyrimidine</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="258"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.6" lower_limit="52.9" upper_limit="66.3"/>
                    <measurement group_id="O2" value="71.2" lower_limit="65.1" upper_limit="77.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Mitomycin and Short-term Fluoropyrimidine</title>
          <description>Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)</description>
        </group>
        <group group_id="E2">
          <title>iceMFP</title>
          <description>Intraperitoneal cisplatin, mitomycin, cisplatin and long-term flouropyrimidine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="217" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="230" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="238" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="226" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="114" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="85" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="164" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="168" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="215" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="236" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="232" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="212" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated AST or ALT</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="83" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="91" subjects_at_risk="263"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="258"/>
                <counts group_id="E2" subjects_affected="165" subjects_at_risk="263"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Yoon-Koo Kang</name_or_title>
      <organization>Asan Medical Center, University of Ulsan College of Medicine</organization>
      <phone>+82-2-3010-3230</phone>
      <email>ykkang@amc.seoul.kr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

